Last 45 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.62 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | 34.52 | 17.08 | 11.06 | 23.06 | 56.95 | 77.99 | 22.70 | — | 58.43 | 66.14 | 64.88 |
| — | — | -39.4% | -78.1% | -51.3% | — | -2.5% | +17.9% | -65.0% | — | -27.1% | -5.4% | -46.2% | |
| P/B Ratio | 2.22 | 1.45 | 2.54 | 1.36 | 0.94 | 1.36 | 2.16 | 2.23 | 2.54 | 2.63 | 2.70 | 3.25 | 2.75 |
| — | +6.5% | +17.9% | -39.1% | -62.8% | -48.1% | -20.2% | -31.3% | -7.7% | +14.5% | -47.6% | -27.0% | -51.8% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | -472.8% | 100.0% | 100.0% | 100.0% | 100.0% | 62.6% | 91.3% | 228.6% | 80.9% | -748.0% | -670.4% |
| — | — | -572.8% | +59.6% | +9.5% | -56.3% | +23.6% | +108.4% | +113.6% | +135.9% | +112.9% | -37.8% | +38.1% | |
| Operating Margin | — | — | -808.9% | -772.2% | -726.6% | -1059.9% | -1589.0% | -1998.6% | -394.0% | 7297.4% | -1093.3% | -973.5% | -888.1% |
| — | — | +49.1% | +61.4% | -84.4% | -114.5% | -45.3% | -105.3% | +55.6% | +999.7% | -37.4% | -38.9% | +30.7% | |
| Net Margin | — | 214.5% | -735.2% | -710.8% | -687.6% | -1001.2% | -1489.5% | -2112.6% | -371.3% | 6894.2% | -1019.2% | -909.8% | -818.1% |
| — | +121.4% | +50.6% | +66.4% | -85.2% | -114.5% | -46.1% | -132.2% | +54.6% | +925.1% | -19.4% | -26.8% | +37.3% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -53.5% | -13.5% | -13.8% | -13.5% | -13.8% | -14.1% | -14.0% | -14.6% | -10.3% | -12.7% | -11.4% | -10.8% | -8.5% |
| — | +4.0% | +1.4% | +7.5% | -34.4% | -11.0% | -23.0% | -35.9% | -21.2% | -15.0% | +14.1% | +1.8% | +42.3% | |
| ROA | -40.6% | -10.8% | -11.1% | -10.7% | -10.5% | -10.9% | -11.5% | -12.0% | -8.4% | -10.4% | -9.5% | -9.0% | -7.0% |
| — | +0.6% | +3.2% | +10.4% | -25.2% | -5.0% | -20.5% | -32.9% | -19.5% | -19.3% | +7.7% | -3.7% | +40.3% | |
| ROIC | — | — | -12.7% | -11.5% | -10.9% | -11.1% | -11.5% | -10.9% | -8.9% | -10.9% | -9.6% | -9.6% | -9.0% |
| — | — | -10.7% | -6.0% | -21.8% | -2.3% | -19.4% | -13.6% | +0.7% | -7.1% | +3.7% | -9.8% | +21.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 12.0% YoY to 5.08x, tightening the short-term liquidity position.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.14 | 0.14 | 0.13 | 0.14 | 0.15 | 0.24 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 | 0.11 |
| — | -42.3% | +24.0% | +31.0% | +42.9% | +119.5% | -7.5% | -1.1% | +1.0% | +3.8% | -3.6% | +40.1% | +40.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.08 | 5.08 | 6.21 | 5.19 | 4.90 | 5.77 | 6.73 | 7.21 | 9.03 | 8.67 | 9.72 | 9.41 | 9.32 |
| — | -12.0% | -7.7% | -27.9% | -45.8% | -33.4% | -30.8% | -23.4% | -3.1% | -9.9% | +48.3% | +30.1% | +34.3% | |
| Quick Ratio | 5.08 | 5.08 | 6.21 | 5.19 | 4.90 | 5.77 | 6.73 | 7.21 | 9.03 | 8.67 | 9.72 | 9.41 | 9.32 |
| — | -12.0% | -7.7% | -27.9% | -45.8% | -33.4% | -30.8% | -23.4% | -3.1% | -9.9% | +48.3% | +30.1% | +34.3% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 45 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonIntellia Therapeutics, Inc.'s current P/E is -3.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Intellia Therapeutics, Inc.'s business trajectory between earnings reports.